Disease index

chemotherapy-induced neutropenia

Oncology · 2010–2020

5decisions
3medicines
1carried consumer input
0individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
pegfilgrastim Treatment of chemotherapy-induced neutropenia in cancer patients receiving chemotherapy with the intention of achieving a cure or substantial remission, who… Mar 2020 Recommended none received
pegfilgrastim Chemotherapy-induced neutropenia in cancer patients receiving chemotherapy with the intention of achieving cure or substantial remission, for those at greater… Nov 2019 Recommended none received
pegfilgrastim Treatment of chemotherapy-induced neutropenia in patients receiving chemotherapy for various malignancies including acute myeloid leukaemia, breast cancer,… Jul 2018 Noted none received
lipegfilgrastim Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy. Mar 2016 Noted input received
filgrastim Similar biological medicinal product (biosimilar) to filgrastim (Neupogen) for reduction of neutropenia duration and clinical sequelae in patients undergoing… Nov 2010 Recommended with restriction no section in document

What the PBS pays

$99M in government benefit over 2024–25, across 138,850 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
lipegfilgrastim $89.6M
filgrastim $4.7M
pegfilgrastim $4.3M

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.